AzTrials
AzTrials

Delivery; ProlongedFORMOMINCT01916681

Foley OR MisO for the Management of Induction

A study testing Cervical Foley & Misoprostol, Misoprostol Alone and Cervical Foley Alone in people with Delivery; Prolonged, run by University of Pennsylvania at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The percentage of women undergoing an induction of labor (IOL) is estimated to be 20% and continues to rise. Simultaneously, the cesarean delivery (CD) rate has continued to increase (2). Induction is a known risk factor for CD. Read more about this study

Who is it for?
Ages 18 years and older, women only
Conditions the study is for
Delivery; Prolonged
What is being tested?
Cervical Foley & Misoprostol, Misoprostol Alone and Cervical Foley Alone
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
491 participants
Where
1 siteUnited States
Study dates
May 2013to Jun 2015
Phase
Interventional
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • Women only
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • All women 18 years of age or greater
  • singleton gestation
  • vertex presentation
  • 37 weeks gestational age or greater
  • undergoing an IOL
  • bishop score less than or equal to 6
  • cervical dilation less than or equal to 2cm

Who cannot join

  • All women less than 18 years of age
  • Contraindication for vaginal delivery
  • Prior cesarean delivery
  • Multiple gestation
  • Intrauterine fetal demise
  • Fetal anomaly
Show all 18Show fewer
  • HIV
  • Unable to consent/ non-English speaking
  • Non-reassuring fetal heart rate
  • Patients with hemolysis elevated liver enzymes and low platelets
  • Eclampsia
  • Intrauterine growth restriction (IUGR) 5th percentile with abnormal dopplers
  • IUGR less than 10th percentile with reversed end diastolic flow
  • Recurrent late decelerations w
  • Continuous contractions more than 3 times in 10 minutes at onset of IOL (given that this is a contraindication to misoprostol use at our institution)
  • Bishop score is greater than 6
  • Cervical dilation greater than or equal to 2cm
  • Confirmed ruptured membranes

Trial locations and contacts

1 site in 1 country.

United States1 site
  • Hospital of the University of Pennsylvania

    Philadelphia, Pennsylvania, 19104

Other trials in United States

About this study

Official title: Foley OR MisO for the Management of Induction (FOR MOMI) Trial

The percentage of women undergoing an induction of labor (IOL) is estimated to be 20% and continues to rise. Simultaneously, the cesarean delivery (CD) rate has continued to increase (2). Induction is a known risk factor for CD. Despite numerous studies evaluating time periods to define a failed IOL, there are no guidelines or accepted definitions of when to call an IOL failed given the incremental gain in vaginal delivery when IOL is prolonged. While decreasing the CD rate is an important primary focus in obstetrics, attention must also be paid to the overall length of labor given that prolonged labor is associated with adverse maternal and neonatal outcomes. Furthermore, a prolonged labor is associated with an increase in direct hospital costs and healthcare utilization. The use of cervical ripening agents, such as vaginal prostaglandin and mechanical dilators, has been demonstrated to reduce labor time and CD rate. In addition to specific individual agents, certain dosing and regimens for IOL and active labor have been compared to evaluate whether a particular dose or regimen can decrease the length of labor and decrease the CD rate. Most of these regimens; however, focus on individual induction agents and few have compared the efficacy of using more than one agent simultaneously. Given the associated risks of prolonged labor and limited data evaluating the use of combined cervical ripening agents, our objective is to evaluate the difference in time to delivery among women who undergo an IOL with four different methods.

Read the detailed description

Prolonged labor increases the risk of maternal and neonatal morbidity as well as increases healthcare costs. There is limited data evaluating the use of two simultaneous induction agents to decrease the time to delivery.

  1. Maternal and neonatal morbidity with prolonged labor The adverse maternal and neonatal morbidity association with prolonged labor has been demonstrated in numerous studies. An increase in maternal risk of post partum hemorrhage and endometritis has been associated with prolonged labor. Cheng et al demonstrated that the risk of post partum hemorrhage and endometritis significantly increased with increasing length of labor. Maghoma et al evaluated the latent phase of labor and found a similar increased risk in endometritis but also noted a significant risk in maternal sepsis with a prolonged latent phase of labor. Neonatal outcomes are similarly improved with a shorter duration of labor. In addition to the risk of chorioamnionitis and decreased 5 minute Apgar score, there is also a significantly increased risk of neonatal intensive care unit admission as well as neonatal sepsis with prolonged labor.
  2. Increased healthcare utilization with prolonged labor Both direct and indirect medical costs have been evaluated in the obstetrics literature. A prolonged labor has been associated with an increase in direct and indirect medical costs as well as an increase in healthcare utilization. Mackenzie et al evaluated the cost of different induction regimens and found a decreased cost for women that remained on the antenatal unit for a shorter period of time.
  3. Use of simultaneous induction agents Pettker et al evaluated the use of a transcervical foley with and without oxytocin and found no difference in mode of delivery or delivery within 24 hours. They found that labor was 2.5 hours shorter with the addition of oxytocin although the study was not powered to see a statistical difference. Other studies have looked at the concurrent use of prostaglandin with cervical foley. Barrilleaux et al evaluated the use of oral misoprostol with cervical foley compared to cervical foley alone and found no difference in time to delivery; however, the use of oral misprostol has well known side effects, including a high rate of tachysystole which was found in this study. Hill et al reported a decreased time to second stage and time to delivery with the use of cervical foley and oral misoprostol compared to vaginal misoprostol alone; however this was a small study that used with a higher, more favorable starting Bishop score in the combined foley+misoprostol group, biasing them away from the null. Standardized time cut offs during IOL were not used in this study. Recently, Carbone et al performed a randomized trial comparing foley bulb and misprostol to misoprostol alone and found a decreased time to delivery among those in the combined group. This study was a small trial with 60 patients in each arm and did not compare the combined agents to cervical foley alone.
  4. Standardization of IOL The optimal length for an IOL is not well established and data on definitions of a failed IOL and prolonged latent phase are lacking. Multiple studies have shown that within 6 hours of oxytocin administration, 60-70% of patients are in active labor. Although data suggest that the longer latent labor is allowed to proceed, the more women that will deliver vaginally, there is also evidence of an increased risk of morbidity, without a large incremental gain. Certain dosing and regimens of individual agents have been evaluated to try and decrease labor; however, studies have not evaluated the use of time cut offs during an IOL to help reduce variation in practice and standardize the IOL process.
Being tested
Cervical Foley & Misoprostol, Misoprostol Alone, Cervical Foley Alone, Cervical Foley & Pitocin
Keywords
Induction, Labor, Cervical foley, Misoprostol, Pitocin, Oxytocin, Cytotec, Delivery, IOL

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Cervical Foley & MisoprostolDevice

    Also called Misoprostol is also known as Cytotec

    A cervical foley combined with misoprostol will be used to induce the patient.

  • Misoprostol AloneDrug

    Also called Misoprostol is also known as Cytotec

    Misoprostol will be used alone to induce the patient

  • Cervical Foley AloneDevice

    A cervical foley alone will be used to induce the patient

  • Cervical Foley & PitocinDevice

    Also called Pitocin is also known as Oxytocin

    A cervical foley combined with pitocin will be used to induce the patient

Study groups in NCT01916681
Study groupRoleWhat they receive
Cervical foley & MisoprostolExperimentalPatients randomized to this arm will receive a cervical foley and misoprostol to induce their labor.
Receives: Device: Cervical Foley & Misoprostol
Misoprostol onlyExperimentalPatients randomized to this arm will receive misoprostol only to induce their labor.
Receives: Drug: Misoprostol Alone
Cervical foley aloneExperimentalPatients randomized to this arm will receive a cervical foley to induce their labor.
Receives: Device: Cervical Foley Alone
Cervical foley & PitocinExperimentalPatients randomized to this arm will receive a cervical foley and pitocin to induce their labor.
Receives: Device: Cervical Foley & Pitocin

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Time to Delivery

    Amount of hours that pass between the start of the induction to delivery.

    Measured: Hours between start of induction to delivery

  2. Length of Stay

    Total maternal length of stay as defined as days from the day the induction began to the day of discharge

    Measured: Days between admit to hospital and discharge

  3. Severe RDS

    Measured: enrollment through neonatal discharge

Secondary outcomes (5)
  1. Mode of Delivery

    Cesarean Delivery

    Measured: Start of induction to delivery

  2. Time to Active Labor

    Measured: Start of induction to active labor

  3. Regional Anesthesia

    Measured: During delivery

  4. Chorioamnionitis

    Measured: Enrollment through deischarge

  5. Maternal Morbidity

    Measured: Enrollment through discharge

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted6 Aug 2013 (estimated)
  2. Study startMay 2013
  3. Primary completionJun 2015
  4. Study completionJun 2015

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Single blind
Who is masked
Outcomes assessor
Enrolment
491 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01916681
Sponsor's protocol ID
817897
Acronym
FORMOMI
Status last verified
Apr 2017
First submitted
30 Jul 2013
Last updated
18 May 2017
Data monitoring committee
Yes
Individual data sharing
No

Publications

  • de Vaan MD, Ten Eikelder ML, Jozwiak M, Palmer KR, Davies-Tuck M, Bloemenkamp KW, Mol BWJ, Boulvain M. Mechanical methods for induction of labour. Cochrane Database Syst Rev. 2023 Mar 30;3(3):CD001233. doi: 10.1002/14651858.CD001233.pub4.

    PubMed 36996264
  • Levine LD, Downes KL, Elovitz MA, Parry S, Sammel MD, Srinivas SK. Mechanical and Pharmacologic Methods of Labor Induction: A Randomized Controlled Trial. Obstet Gynecol. 2016 Dec;128(6):1357-1364. doi: 10.1097/AOG.0000000000001778.

    PubMed 27824758

Questions about this trial

What is this clinical trial studying?

A study testing Cervical Foley & Misoprostol, Misoprostol Alone and Cervical Foley Alone in people with Delivery; Prolonged, run by University of Pennsylvania at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 7 inclusion and 18 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 18 May 2017. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Yes. Results are posted in the registry (first posted 21 Dec 2016). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Time to Delivery (time frame: Hours between start of induction to delivery). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT01916681, which also lists 2 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 May 2017.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in